These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30425069)

  • 1. Timing of treatment of smoldering myeloma: delay until progression.
    Kumar SK
    Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of treatment of smoldering myeloma: early treatment.
    Mateos MV; González-Calle V
    Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
    Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
    Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
    Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H
    Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixazomib as treatment for pyoderma gangrenosum associated with IgA smoldering multiple myeloma.
    Cespedes DA; Gallitano SM; Bhutani D
    Ann Hematol; 2022 Feb; 101(2):441-442. PubMed ID: 33860355
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen.
    Solomou EE; Marnellos P; Agathokleous A; Kyriakou G; Georgiou S; Symeonidis A
    Ann Hematol; 2019 Nov; 98(11):2625-2626. PubMed ID: 31650288
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide.
    Mello RB; Vale ECSD
    An Bras Dermatol; 2019 Jul; 94(3):337-340. PubMed ID: 31365665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic patterns of progression in smoldering multiple myeloma.
    Bolli N; Maura F; Minvielle S; Gloznik D; Szalat R; Fullam A; Martincorena I; Dawson KJ; Samur MK; Zamora J; Tarpey P; Davies H; Fulciniti M; Shammas MA; Tai YT; Magrangeas F; Moreau P; Corradini P; Anderson K; Alexandrov L; Wedge DC; Avet-Loiseau H; Campbell P; Munshi N
    Nat Commun; 2018 Aug; 9(1):3363. PubMed ID: 30135448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 May; 13(5):501-517. PubMed ID: 32290723
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
    Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
    Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
    Fonseca R; Gonzalez-Velez M
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma.
    Merz M; Hielscher T; Schult D; Mai EK; Raab MS; Hillengass J; Seckinger A; Hose D; Granzow M; Jauch A; Goldschmidt H
    Leukemia; 2020 Apr; 34(4):1192-1196. PubMed ID: 31712777
    [No Abstract]   [Full Text] [Related]  

  • 18. Smoldering Myeloma Treatment: Who, What, and When.
    Mejia Saldarriaga M; Rossi A
    Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical approach to the management of smoldering myeloma.
    Joseph NS; Lonial S
    Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.